vs
Alector, Inc.（ALEC）与Aligos Therapeutics, Inc.（ALGS）财务数据对比。点击上方公司名可切换其他公司
Alector, Inc.的季度营收约是Aligos Therapeutics, Inc.的36.9倍（$6.2M vs $169.0K）。Alector, Inc.净利率更高（-597.5% vs -11763.9%，领先11166.4%）。Aligos Therapeutics, Inc.同比增速更快（-72.1% vs -88.5%）。过去两年Alector, Inc.的营收复合增速更高（-37.4% vs -50.7%）
Alector是一家临床阶段生物制药企业，专注于神经退行性疾病的免疫疗法研发，管线覆盖阿尔茨海默病、额颞叶痴呆、帕金森病等未被满足的医疗需求，主要在美国运营，与全球药企合作推进候选药物的临床试验。
Aligos Therapeutics是一家临床阶段生物制药企业，专注于开发针对流行性肝病与病毒感染的新型靶向疗法，核心管线覆盖慢性乙型肝炎、非酒精性脂肪性肝炎等适应症，通过自主研发推进药物落地，满足全球未被满足的医疗需求。
ALEC vs ALGS — 直观对比
营收规模更大
ALEC
是对方的36.9倍
$169.0K
营收增速更快
ALGS
高出16.4%
-88.5%
净利率更高
ALEC
高出11166.4%
-11763.9%
两年增速更快
ALEC
近两年复合增速
-50.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $6.2M | $169.0K |
| 净利润 | $-37.3M | $-19.9M |
| 毛利率 | — | — |
| 营业利润率 | -634.4% | -12907.7% |
| 净利率 | -597.5% | -11763.9% |
| 营收同比 | -88.5% | -72.1% |
| 净利润同比 | -1696.9% | 75.8% |
| 每股收益（稀释后） | $-0.34 | $4.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALECALGS
| Q4 25 | $6.2M | $169.0K | ||
| Q3 25 | $3.3M | $741.0K | ||
| Q2 25 | $7.9M | $965.0K | ||
| Q1 25 | $3.7M | $311.0K | ||
| Q4 24 | $54.2M | $606.0K | ||
| Q3 24 | $15.3M | $1.3M | ||
| Q2 24 | $15.1M | $1.1M | ||
| Q1 24 | $15.9M | $694.0K |
净利润ALECALGS
| Q4 25 | $-37.3M | $-19.9M | ||
| Q3 25 | $-34.7M | $-31.5M | ||
| Q2 25 | $-30.5M | $-15.9M | ||
| Q1 25 | $-40.5M | $43.1M | ||
| Q4 24 | $-2.1M | $-82.2M | ||
| Q3 24 | $-42.2M | $-19.3M | ||
| Q2 24 | $-38.7M | $5.1M | ||
| Q1 24 | $-36.1M | $-34.9M |
营业利润率ALECALGS
| Q4 25 | -634.4% | -12907.7% | ||
| Q3 25 | -1153.6% | -3827.4% | ||
| Q2 25 | -433.6% | -1924.0% | ||
| Q1 25 | -1216.5% | -6187.5% | ||
| Q4 24 | -13.4% | -3393.2% | ||
| Q3 24 | -315.7% | -1610.5% | ||
| Q2 24 | -302.4% | -2489.5% | ||
| Q1 24 | -275.0% | -3176.7% |
净利率ALECALGS
| Q4 25 | -597.5% | -11763.9% | ||
| Q3 25 | -1063.4% | -4256.0% | ||
| Q2 25 | -387.7% | -1643.8% | ||
| Q1 25 | -1101.6% | 13854.7% | ||
| Q4 24 | -3.8% | -13556.1% | ||
| Q3 24 | -275.2% | -1540.7% | ||
| Q2 24 | -256.4% | 477.0% | ||
| Q1 24 | -227.0% | -5023.5% |
每股收益（稀释后）ALECALGS
| Q4 25 | $-0.34 | $4.23 | ||
| Q3 25 | $-0.34 | $-3.04 | ||
| Q2 25 | $-0.30 | $-1.53 | ||
| Q1 25 | $-0.41 | $-2.11 | ||
| Q4 24 | $-0.02 | $-13.10 | ||
| Q3 24 | $-0.43 | $-3.07 | ||
| Q2 24 | $-0.40 | $0.81 | ||
| Q1 24 | $-0.38 | $-5.58 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $256.0M | $77.8M |
| 总债务越低越好 | $10.0M | — |
| 股东权益账面价值 | $30.6M | $53.5M |
| 总资产 | $293.2M | $88.5M |
| 负债/权益比越低杠杆越低 | 0.33× | — |
8季度趋势，按日历期对齐
现金及短期投资ALECALGS
| Q4 25 | $256.0M | $77.8M | ||
| Q3 25 | $291.1M | $99.1M | ||
| Q2 25 | $307.3M | $122.9M | ||
| Q1 25 | $354.6M | $137.9M | ||
| Q4 24 | $413.4M | $56.9M | ||
| Q3 24 | $457.2M | $74.9M | ||
| Q2 24 | $503.3M | $94.5M | ||
| Q1 24 | $562.1M | $112.7M |
总债务ALECALGS
| Q4 25 | $10.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $10.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ALECALGS
| Q4 25 | $30.6M | $53.5M | ||
| Q3 25 | $57.7M | $71.8M | ||
| Q2 25 | $71.2M | $101.9M | ||
| Q1 25 | $94.6M | $116.4M | ||
| Q4 24 | $126.8M | $-29.0M | ||
| Q3 24 | $118.9M | $50.1M | ||
| Q2 24 | $150.6M | $67.2M | ||
| Q1 24 | $178.9M | $59.8M |
总资产ALECALGS
| Q4 25 | $293.2M | $88.5M | ||
| Q3 25 | $335.3M | $109.8M | ||
| Q2 25 | $356.4M | $134.7M | ||
| Q1 25 | $408.3M | $150.7M | ||
| Q4 24 | $468.3M | $70.1M | ||
| Q3 24 | $516.0M | $88.4M | ||
| Q2 24 | $570.7M | $108.8M | ||
| Q1 24 | $635.5M | $127.9M |
负债/权益比ALECALGS
| Q4 25 | 0.33× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.08× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-41.7M | $-21.7M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ALECALGS
| Q4 25 | $-41.7M | $-21.7M | ||
| Q3 25 | $-32.5M | $-24.3M | ||
| Q2 25 | $-49.0M | $-15.5M | ||
| Q1 25 | $-60.8M | $-20.9M | ||
| Q4 24 | $-55.0M | $-18.4M | ||
| Q3 24 | $-50.7M | $-20.1M | ||
| Q2 24 | $-62.8M | $-19.5M | ||
| Q1 24 | $-61.3M | $-22.7M |
自由现金流ALECALGS
| Q4 25 | — | — | ||
| Q3 25 | $-32.5M | — | ||
| Q2 25 | $-49.1M | — | ||
| Q1 25 | $-60.8M | — | ||
| Q4 24 | $-55.2M | — | ||
| Q3 24 | $-50.9M | — | ||
| Q2 24 | $-63.1M | — | ||
| Q1 24 | $-61.9M | — |
自由现金流率ALECALGS
| Q4 25 | — | — | ||
| Q3 25 | -997.6% | — | ||
| Q2 25 | -623.0% | — | ||
| Q1 25 | -1655.0% | — | ||
| Q4 24 | -101.8% | — | ||
| Q3 24 | -332.1% | — | ||
| Q2 24 | -418.6% | — | ||
| Q1 24 | -389.3% | — |
资本支出强度ALECALGS
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | 2.2% | — | ||
| Q1 24 | 3.4% | — |
现金转化率ALECALGS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -3.85× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
